Ticker: VALN

07:40am, Monday, Mar 23, 2026

Pfizer and Valneva Aim for Lyme Disease Vaccine Approval Despite Mixed Trial Outcome

Pfizer and Valneva announce plans to seek approval for a Lyme disease vaccine after a Phase 3 trial showed over 70% efficacy but missed its primary statistical target.